tbuckley/cabot-search huggingface dataset:
Multimodal Image-Guided Surgical and Photodynamic Interventions in Head and Neck Cancer: From Primary Tumor to Metastatic Drainage
Authors: Nidal Muhanna, Liyang Cui, Harley Chan, Laura Burgess, Cheng S. Jin, Thomas D. MacDonald, Elizabeth Huynh, Fan Wang, Juan Chen, Jonathan C. Irish, Gang Zheng
Journal: Clinical Cancer Research (2015)

Abstract Purpose: The low survival rate of head and neck cancer (HNC) patients is attributable to late disease diagnosis and high recurrence rate. Current HNC staging has inadequate accuracy and low sensitivity for effective diagnosis and treatment management. The multimodal porphyrin lipoprotein-mimicking nanoparticle (PLP), intrinsically capable of positron emission tomography (PET), fluorescence imaging, and photodynamic therapy (PDT), shows great potential to enhance the accuracy of HNC staging and potentially HNC management. Experimental Design: Using a clinically relevant VX-2 buccal carcinoma rabbit model that is able to consistently develop metastasis to regional lymph nodes after tumor induction, we investigated the abilities of PLP for HNC diagnosis and management. Results: PLPs facilitated accurate detection of primary tumor and metastatic nodes (their PET image signal to surrounding muscle ratios were 10.0 and 7.3, respectively), and provided visualization of the lymphatic drainage from tumor to regional lymph nodes by both preoperative PET and intraoperative fluorescence imaging, allowing the identification of unknown primaries and recurrent tumors. PLP-PDT significantly enhanced cell apoptosis in mouse tumors (73.2% of PLP-PDT group vs 7.1% of PLP alone group) and demonstrated complete eradication of primary tumors and obstruction of tumor metastasis in HNC rabbit model without toxicity in normal tissues or damage to adjacent critical structures. Conclusions: PLPs provide a multimodal imaging and therapy platform that could enhance HNC diagnosis by integrating PET/computed tomography and fluorescence imaging, and improve HNC therapeutic efficacy and specificity by tailoring treatment via fluorescence-guided surgery and PDT. Clin Cancer Res; 22(4); 961–70. ©2015 AACR.
Tuberculosis after lung transplantation, Germany, 1993-2012
Authors: Felix C. Ringshausen, Hendrik Suhling, Franz-Christoph Bange, Tobias Welte, Jens Gottlieb
Journal: European Respiratory Journal (2013)

Rationale:  Solid organ transplant recipients are at increased risk of developing active tuberculosis (TB). Among those, lung transplant recipients (LTR) are considered to have the highest risk of TB. At our institution no routine screening for latent TB infection and no preventive chemotherapy prior to lung/heart-lung transplantation (LTX) is performed, primarily due to the low incidence of TB in the general population, the risk of drug toxicity and the limitations of available screening tests.   Objective:  To determine the cumulative incidence of active TB after LTX.   Methods:  We analysed all LTR outpatient visits, which had been entered prospectively into an electronic database over a 19-year period between June 1993 and June 2012.   Results:  Overall, 28,538 outpatient visits from 1,146 LTRs were analysed, resulting in a total observational period of 6,608 person-years and a median follow-up time of 56 (IQR 21–96) month. Five subjects (crude rate 0.4%) developed TB, resulting in a cumulative incidence rate of 75.7 (95% CI 27.7–167.7) per 100,000 person-years. The corresponding cumulative incidence in the general population was 10.9 (95% CI 10.85–10.95) per 100,000 person-years.   Conclusion:  To our knowledge, this is the largest cohort of LTRs observed regarding the development of active TB so far. The observed TB incidence after LTX was moderately higher than the incidence in the general population, but considerably lower than previously reported. Our results support the recent TBNET consensus statement, which recommends refraining from routine latent TB screening of transplant candidates in TB low burden settings as no benefit is to be expected. However, surveillance within frequent and centre-based follow-up is crucial.
WITHDRAWN: Physiological and gene expressional alternation in obesity animal model for ADME/PK characterization
Authors: Sung-Hoon Ahn
Journal: Asian Journal of Pharmaceutical Sciences (2015)

This article has been withdrawn at the request of the author(s) and/or editor. The Publisher apologizes for any inconvenience this may cause. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
OC-094 Interim results of a european, multi-centre, prospective, observational study of permacol™ collagen paste injection for the treatment of anal fistulas
Authors: P Giordano, P Sileri, S Buntzen, A Stuto, J Nunoo-Mensah, L Lenisa, B Singh, O Thorlacius-Ussing, B Griffiths, D Ziyaie
Journal: Gut (2015)

<h3>Introduction</h3> Historically, the treatment of anal fistulas has required a compromise between successful fistula healing and preservation of continence. The aim of this study (NCT01624350) is to evaluate clinical outcomes of anal fistulas treated with Permacol™ collagen paste. <h3>Method</h3> Patients (N = 98) with magnetic resonance imaging-confirmed intersphincteric or transsphincteric anal fistulas, cryptoglandular primary or recurrent, from ten European sites were treated with Permacol™ collagen paste. Fistula healing, adverse events, and patient satisfaction were assessed up to 12 months post-surgery, with fistula healing at 6 months confirmed by clinical assessment as the primary endpoint. Cox regression analyses were performed to determine if patient or fistula characteristics correlate with better healing. <h3>Results</h3> The median follow-up was 26.8 weeks (range 0.1–62.4 weeks), with 87 and 46 patients having healing data at 6 months and 12 months, respectively. At 6 months follow-up, 51 (58.6%) patients exhibited a clinically-healed anal fistula, including 20/35 (57.1%) that were recurrent at the time of treatment. At 12 months, 19 (41.3%) patients were healed. Younger patients and those with evidence of expulsion or leakage of Permacol™ collagen paste were the only variables associated with a significantly increased risk of failure (p = 0.0017 and p = 0.0068, respectively). A total of six serious adverse events were reported, four of which (perianal abscess, n = 2; non-healing fistula tract, n = 1; complex regional pain syndrome, n = 1) were possibly related to the device and/or the procedure. Continence was preserved throughout the follow-up. At their last visit, over 70% of patients reported being satisfied or very satisfied with their operation, indicating that some patients were satisfied even though their fistula did not heal. <h3>Conclusion</h3> These preliminary results demonstrate that Permacol™ collagen paste is a well-tolerated, sphincter-sparing technique for the treatment of anal fistulas with low morbidity. <h3>Disclosure of interest</h3> P. Giordano Grant/Research Support from: Covidien, Consultant for: Covidien, Speaker Bureau of: Covidien, P. Sileri Grant/Research Support from: Covidien, S. Buntzen Grant/Research Support from: Covidien, Speaker Bureau of: Medtronic, A. Stuto Grant/Research Support from: Covidien, J. Nunoo-Mensah Grant/Research Support from: Covidien, L. Lenisa Grant/Research Support from: Covidien, B. Singh Grant/Research Support from: Covidien, Speaker Bureau of: Covidien, O. Thorlacius-Ussing Grant/Research Support from: Covidien, B. Griffiths Grant/Research Support from: Covidien, D. Ziyaie Grant/Research Support from: Covidien, Speaker Bureau of: Covidien.
Expression of types I, II, and III TGF-beta receptors in human glomerulonephritis.
Authors: T Yamamoto, T Watanabe, N Ikegaya, Y Fujigaki, K Matsui, H Masaoka, M Nagase, A Hishida
Journal: Journal of the American Society of Nephrology (1998)

Protein and mRNA expression of transforming growth factor-beta (TGF-beta) receptor type I (TbetaRI), type II (TbetaRII), and type III (TbetaRIII) were studied in serial sections of kidney samples obtained from patients with glomerulonephritis. In minimal change disease, weak expression of TbetaRI and TbetaRII was observed mainly in glomerular endothelial cells, peritubular capillaries, and interstitial arteriolar endothelial cells, whereas TbetaRIII expression was found mainly in the interstitium. Expression of all three TGF-beta receptors (TbetaR) was increased remarkably in glomerular and Bowman's capsular cells comprising the tuft adhesions to Bowman's capsules in glomerulonephritis with increased matrix accumulation, including IgA nephropathy, lupus nephritis, focal and segmental glomerulosclerosis, myeloperoxidase-antineutrophil cytoplasmic antibody-associated crescentic glomerulonephritis, and membranoproliferative glomerulonephritis. Increased expression of the three TbetaR was also seen in glomerular epithelial cells in the vicinity of glomerulosclerotic lesions, in crescent cells, and in some tubules and infiltrative mononuclear cells found in the periglomerular and tubulointerstitial lesions with increased matrix deposition. In contrast, no remarkable TbetaRII expression was noted in mesangial proliferative lesions in IgA nephropathy, lupus nephritis, and membranoproliferative glomerulonephritis. These data suggest that distinctive modulation of TbetaR expression may be involved in the development of adhesive, sclerotic, and proliferative renal lesions in human glomerulonephritis.
Neurodevelopmental Outcomes of Preterm Infants Fed High-Dose Docosahexaenoic Acid
Authors: Maria Makrides, Robert A. Gibson, Andrew J. McPhee, Carmel T. Collins, Peter G. Davis, Lex W. Doyle, Karen Simmer, Paul B. Colditz, Scott Morris, Lisa G. Smithers, Kristyn Willson, Philip Ryan
Journal: JAMA (2009)
Pediatric Global Health Education
Authors: Michael B. Pitt, Sophia P. Gladding, Parminder S. Suchdev, Cynthia R. Howard
Journal: JAMA Pediatrics (2015)

Recent outbreaks of diseases erroneously thought by many to be contained by borders or eliminated by vaccines have highlighted the need for proper training of all residents in global health. Beyond infectious diseases, all pediatricians should know how to care for other conditions in global child health, ranging from malnutrition to the nuances of care for immigrant and refugee children. The call for broader education for pediatric residents in global health has been increasing over the last decade, with all major pediatric organizations underscoring its importance in statement and action. Herein, the current status of global child health education in pediatric residency training in the United States is summarized, highlighting where it has been, where it is now, and where it should go next.
Food-borne outbreak of norovirus infection in a French military parachuting unit, April 2011
Authors: A Mayet, V Andréo, G Bédubourg, S Victorion, J Y Plantec, B Soullié, J B Meynard, J J Dedieu, P Y Polvèche, R Migliani
Journal: Eurosurveillance (2011)

On 13 April 2011 the medical service of a French military parachuting unit reported an outbreak of acute gastroenteritis involving 147 persons among the military personnel. Meals suspected to have caused the outbreak (pasta and some raw vegetables) were tested for norovirus by PCR. The same norovirus (genogroup I) was found in some of the food items consumed by the cases and in a cook who prepared the meals.
Effects of Combined Chemotherapy on Sarcoma 180, With Special Reference to Food Intake, Body-Weight Changes, and Survival Time&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Louis Barvick, Louis H. Goodson
Journal: JNCI Journal of the National Cancer Institute (1954)

Effects of Combined Chemotherapy on Sarcoma 180, With Special Reference to Food Intake, Body-Weight Changes, and Survival Time Louis Barvick, Louis Barvick Chemistry Research Division, Midwest Research Institute, Kansas City, Mo. Search for other works by this author on: Oxford Academic PubMed Google Scholar Louis H. Goodson Louis H. Goodson Chemistry Research Division, Midwest Research Institute, Kansas City, Mo. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 15, Issue 1, August 1954, Pages 177–189, https://doi.org/10.1093/jnci/15.1.177 Published: 01 August 1954 Article history Received: 19 April 1954 Published: 01 August 1954
Lipocortin-1 is an endogenous inhibitor of ischemic damage in the rat brain.
Authors: J K Relton, P J Strijbos, C T O'Shaughnessy, F Carey, R A Forder, F J Tilders, N J Rothwell
Journal: The Journal of Experimental Medicine (1991)

Lipocortin-1 (annexin-1) is an endogenous peptide with antiinflammatory properties. We have previously demonstrated lipocortin immunoreactivity in certain glial cells and neurons in the rat brain (Strijbos, P.J.L.M., F.J.H. Tilders, F. Carey, R. Forder, and N.J. Rothwell. 1990. Brain Res. In press.), and have shown that an NH2-terminal fragment (1-188) of lipocortin-1 inhibits the central and peripheral actions of cytokines on fever and thermogenesis in the rat in vivo (Carey, F., R. Forder, M.D. Edge, A.R. Greene, M.A. Horan, P.J.L.M. Strijbos, and N.J. Rothwell. 1990. Am. J. Physiol. 259:R266; and Strijbos, P.J.L.M., J.L. Browning, M. Ward, R. Forder, F. Carey, M.A. Horan, and N.J. Rothwell. 1991. Br. J. Pharmacol. In press.). We now report that intracerebroventricular administration of lipocortin-1 fragment causes marked inhibition of infarct size (60%) and cerebral edema (46%) measured 2 h after cerebral ischemia (middle cerebral artery occlusion) in the rat in vivo. The lipocortin-1 fragment was effective when administered 10 min after induction of ischemia. Ischemia caused increased expression of lipocortin-1 around the area of infarction as demonstrated by immunocytochemistry. Intracerebroventricular injection of neutralizing antilipocortin-1 fragment antiserum increased the size of infarct (53%) and the development of edema (29%). These findings indicate that lipocortin-1 is an endogenous inhibitor of cerebral ischemia with considerable therapeutic potential.
Focal Segmental Glomerulosclerosis
Authors: MELVIN M. SCHWARTZ, JONI EVANS, RAY BAIN, STEPHEN M. KORBET
Journal: Journal of the American Society of Nephrology (1999)

Abstract. The cellular lesion (CELL), seen in some patients with primary focal segmental glomerulosclerosis (FSGS), comprises proliferation, hypertrophy, and pathologic changes in the cells overlying the glomerular scar. The prognosis of the cellular lesion was retrospectively studied in 100 patients with FSGS (43 had FSGS-CELL and 57 had FSGS without the cellular lesion (classic segmental scar [CS]). Patients with the FSGS-CELL lesion were more often black and severely proteinuric and developed more end-stage renal disease (ESRD). Nephrotic patients with FSGS-CELL ( n = 39) were more proteinuric at presentation than patients with FSGS-CS ( n = 36). ESRD developed more frequently in patients with the FSGS-CELL (17 of 39, 44% versus 5 of 36, 14%, P = 0.005), and patients with extensive FSGS-CELL (≥ 20% glomeruli) were mainly black (94%), severely nephrotic (67%, &gt;10 g/d), and had a poor response to treatment (23% remission). In nephrotic patients, initial serum creatinine, interstitial expansion ≥20%, and CELL independently predicted ESRD. However, the rates of remission in treated nephrotic patients with FSGS-CELL and FSGS-CS were the same (9 of 17, 53% versus 17 of 39, 52%), and patients in both groups who achieved a remission had a 5-yr survival of 100%. Steroid treatment was the only variable that predicted remission. Patients with the FSGS-CELL have an increased prevalence of ESRD, but the improved prognosis associated with remission is so significant that a therapeutic trial is warranted in all nephrotic FSGS patients, regardless of the presence of the cellular lesion.
VLA4 Blockade In Acute Myeloid Leukemia
Authors: Yao-Te Hsieh, Enzi Jiang, Jennifer Pham, Hye-Na Kim, Hisham Abdel-Azim, Sajad Khazal, Gesine Bug, Gabriele Spohn, Halvard Bonig, Yong-Mi Kim
Journal: Blood (2013)
Phase I Study of the Investigational NEDD8-Activating Enzyme Inhibitor Pevonedistat (TAK-924/MLN4924) in Patients with Advanced Solid Tumors
Authors: John Sarantopoulos, Geoffrey I. Shapiro, Roger B. Cohen, Jeffrey W. Clark, John S. Kauh, Glen J. Weiss, James M. Cleary, Devalingam Mahalingam, Michael D. Pickard, Hélène M. Faessel, Allison J. Berger, Kristine Burke, George Mulligan, Bruce J. Dezube, R. Donald Harvey
Journal: Clinical Cancer Research (2015)

To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodynamics in patients with advanced nonhematologic malignancies.Pevonedistat was administered via 60-minute intravenous infusion on days 1 to 5 (schedule A, n = 12), or days 1, 3, and 5 (schedules B, n = 17, and C, n = 19) of 21-day cycles. Schedule B included oral dexamethasone 8 mg before each pevonedistat dose. Dose escalation proceeded using a Bayesian continual reassessment method. Tumor response was assessed by RECIST 1.0.Schedule A MTD was 50 mg/m(2); based on the severity of observed hepatotoxicity, this schedule was discontinued. Schedules B and C MTDs were 50 and 67 mg/m(2), respectively. DLTs on both these schedules included hyperbilirubinemia and elevated aspartate aminotransferase. There were no grade ≥ 3 treatment-related serious adverse events reported on schedules B or C. Twenty-three (74%) evaluable patients on schedules B and C had stable disease. Intermittent dexamethasone use did not significantly influence pevonedistat pharmacokinetics. NAE inhibition by pevonedistat was demonstrated in multiple tumor types via IHC detection of pevonedistat-NEDD8 adduct and accumulation of Cullin-RING ligase substrates CDT1 and NRF2 in tumor biopsies.Pevonedistat was generally well tolerated on a day 1, 3, 5 schedule every 3 weeks with an MTD between 50 mg/m(2) and 67 mg/m(2). DLTs were predominantly hepatic enzyme elevations. Pharmacodynamic studies demonstrated that pevonedistat inhibited NAE in tumors.
Deficiency of IL-12p35 improves cardiac repair after myocardial infarction by promoting angiogenesis
Authors: Xiaoyu Kan, Yina Wu, Youcai Ma, Congcong Zhang, Ping Li, Lifei Wu, Shuai Zhang, Yulin Li, Jie Du
Journal: Cardiovascular Research (2015)

IL-12p35 is a pro-inflammatory cytokine that participates in a variety of inflammatory diseases. This study aimed to determine whether IL-12 regulates cardiac injury and repair following acute myocardial infarction (AMI) and investigate the underlying mechanisms. Mice with AMI showed a marked increase in IL-12p35 expression of ischaemic cardiac tissues. IL-12 was mainly produced by CD11b+ monocytes. Cardiac functions were significantly improved in IL-12p35 knockout (p35-KO) mice compared with wild-type (WT) littermates in response to AMI. IL-12p35 deficiency attenuated the infarct scar and hypertrophy compared with WT mice. RNA transcriptome sequencing and quantitative RT–PCR analysis of CD11b+ monocytes isolated from WT and p35-KO ischaemic hearts revealed a distinct transcriptional profile in p35-KO CD11b+ monocytes, displaying pro-angiogenesis and anti-inflammation properties. Angiogenesis was enhanced in p35-KO mice with AMI and hindlimb ischaemia. Moreover, tube formation assay and Matrigel plug analysis demonstrated that IL-12 inhibition of angiogenesis was dependent on monocytes. IL-12p35 deficiency inhibited inflammation by reducing chemokine production and monocyte infiltration into the heart. Finally, administration of an IL-12p35-neutralizing antibody limited AMI-induced inflammatory cell infiltration into the heart and improved angiogenesis and cardiac function. Deficiency of IL-12p35 limited AMI-induced cardiac injury by promoting pro-angiogenesis and anti-inflammatory functions of monocytes.
Dose escalation of cytotoxic drugs using haematopoietic growth factors: A randomized trial to determine the magnitude of increase provided by GM-CSF
Authors: M. Pfreundschuh, D. Hasenclever, M. Loeffler, G. Ehninger, N. Schmitz, H. Kirchner, P. Koch, B. Lathan, U. Rueffer, M. Sextro, J. Franklin, H. Tesch, V. Diehl
Journal: Annals of Oncology (2001)
Dangerous to extrapolate local audit findings
Authors: R H Mcallister-Williams, I N Ferrier
Journal: BMJ (1996)

EDITOR,—Alice McGrath and Graham Jackson's survey of neuroleptic prescribing to residents of nursing homes in Glasgow1 has been given extensive coverage by the BBC. It was reported that the survey showed an alarmingly high level of neuroleptic prescribing, that 88% of patients received them inappropriately, and that significant numbers of residents were receiving high doses. These headlines were repeated regularly through 8 March on Radios 4 and 5. On reading McGrath and …
In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins
Authors: GQ Chen, J Zhu, XG Shi, JH Ni, HJ Zhong, GY Si, XL Jin, W Tang, XS Li, SM Xong, ZX Shen, GL Sun, J Ma, P Zhang, TD Zhang, C Gazin, T Naoe, SJ Chen, ZY Wang, Z Chen
Journal: Blood (1996)
Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells
Authors: W Said, K Chien, S Takeuchi, T Tasaka, H Asou, SK Cho, S de Vos, E Cesarman, DM Knowles, HP Koeffler
Journal: Blood (1996)
NCCN: Your Best Resource in the Fight Against Cancer
Authors: William T. McGivney
Journal: Journal of the National Comprehensive Cancer Network (2015)

An oncologist came up to me not that many years ago and said, “We thank NCCN; NCCN is our last, best hope.” Those words still ring true. The policies and processes in the cancer care delivery system increasingly attempt to limit the autonomy and authority of oncologists and other clinicians to decide—in concert with patients and caregivers—what is best for patients. The strength of NCCN has been and shall be the ongoing commitment to integrating scientific evaluation of the results of clinical research with the vast experience, expertise, and clinical judgment of NCCN panel members and others to establish evidence-based/expert-based recommendations regarding appropriate therapeutic options. The NCCN Guidelines stand as testament to the dedication and commitment of those who, through the years, have painstakingly established the thousands of pages of recommendations. The NCCN Guidelines quickly became the standard of oncology care in the United States in the early 2000s. Soon thereafter, payers began using guideline recommendations as the basis for coverage policy. NCCN was fastidious and driven about timely updating and communicating recommendations about new technologies and important issues. NCCN also was exceedingly adept at applying formats to attract and facilitate the work of decision-makers (eg, physicians, practice managers, payers). As an example of this, the NCCN Drugs & Biologics Compendium (NCCN Compendium), a derivative of the NCCN Guidelines, became the basis for and the driver of coverage policy for drugs and biologics.
Enhanced in vivo antitumor efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumor targeting and Hsp90 inhibition
Authors: Yao Jiang, Nan Yang, Huifeng Zhang, Bo Sun, Chunying Hou, Chao Ji, Ji Zheng, Yanyong Liu, Pingping Zuo
Journal: Journal of Controlled Release (2015)